Overview

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Jiangsu Nutai Biologics Co., Ltd
Collaborator:
Chinese Academy of Medical Sciences